AgomAb Therapeutics

Franklin Rooseveltlaan 348 126

9000 Gent

BE

AgomAb Therapeutics

Foundation date

13/04/2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Upcoming events

Latest news

  • Imec-onderzoekers leggen basis voor in vivo detectie van traag groeiende hersentumoren, met dank aan hyperspectrale camera

    Friday February 3rd 2023

  • Weber joins Vivactis Group to reinforce its Market Access capabilities

    Thursday February 2nd 2023

  • Mithra CDMO announces collaboration with VaRi Bioscience for the development of a long-acting product in women’s health

    Thursday February 2nd 2023

Jobs by AgomAb Therapeutics